The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
The new single-pill therapy combines cilnidipine, telmisartan and metoprolol, bringing together three established antihypertensive agents with complementary mechanisms
The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
20 among them to receive $20,000 grants
The results were consistent across both the 10 mg and 40 mg treatment arms
The new device promises faster, more efficient cardiac procedures while maintaining the safety and effectiveness clinicians expect
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
The collaboration promises expanded funding for Thai universities, research institutes, companies, and global research partners working in Thailand
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
